These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11883334)

  • 21. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
    Esteva FJ; Hortobagyi GN
    Breast; 2006 Jun; 15(3):301-12. PubMed ID: 16230014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipoprotein profile in breast cancer women: effect of tamoxifen treatment.
    Dziewulska-Bokiniec A; Wojtacki J; Skokowski J; Wróblewska M
    Neoplasma; 1994; 41(6):337-40. PubMed ID: 7870217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial.
    Tominaga T; Kimijima I; Kimura M; Takatsuka Y; Takashima S; Nomura Y; Kasumi F; Yamaguchi A; Masuda N; Noguchi S; Eshima N
    Jpn J Clin Oncol; 2010 Jul; 40(7):627-33. PubMed ID: 20382637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer.
    Lien EA; Anker G; Ueland PM
    J Steroid Biochem Mol Biol; 1995 Nov; 55(2):229-31. PubMed ID: 7495702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
    Hozumi Y; Suemasu K; Takei H; Aihara T; Takehara M; Saito T; Ohsumi S; Masuda N; Ohashi Y
    Ann Oncol; 2011 Aug; 22(8):1777-82. PubMed ID: 21285133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations.
    Kusama M; Kaise H; Nakayama S; Ota D; Misaka T; Aoki T
    Breast Cancer Res Treat; 2004 Nov; 88(1):9-16. PubMed ID: 15538041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
    Kataoka M; Yamaguchi Y; Moriya Y; Sawada N; Yasuno H; Kondoh K; Evans DB; Mori K; Hayashi S
    Oncol Rep; 2012 Feb; 27(2):303-10. PubMed ID: 22076074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Duration of tamoxifen effect on lipidemic profile of postmenopausal breast cancer patients following deprivation of treatment.
    Markopoulos C; Chrissochou M; Antonopoulou Z; Xepapadakis G; Papadiamantis J; Tzoracoleftherakis E; Gogas H
    Oncology; 2006; 70(4):301-5. PubMed ID: 17047401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer.
    Koopal C; Janssen-Heijnen ML; van de Wouw AJ; van den Bergh JP
    Breast; 2015 Apr; 24(2):153-8. PubMed ID: 25618224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The serum estradiol concentration is the main determinant of the estradiol concentration in normal breast tissue.
    Depypere HT; Bolca S; Bracke M; Delanghe J; Comhaire F; Blondeel P
    Maturitas; 2015 May; 81(1):42-5. PubMed ID: 25721699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial.
    Kroiss R; Fentiman IS; Helmond FA; Rymer J; Foidart JM; Bundred N; Mol-Arts M; Kubista E
    BJOG; 2005 Feb; 112(2):228-33. PubMed ID: 15663589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
    Buzdar AU
    Oncologist; 2003; 8(4):335-41. PubMed ID: 12897330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy.
    Markopoulos C; Chrissochou M; Michailidou A; Tzoracoleftherakis E; Xepapadakis G; Papadiamantis J; Misitzis J; Zobolas V; Bafaloukos D; Gogas H
    Anticancer Drugs; 2005 Sep; 16(8):879-83. PubMed ID: 16096437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer.
    Morales M; Santana N; Soria A; Mosquera A; Ordovás J; Nóvoa J; Betancor P; Valerón PF; Díaz-Chico B; Chirino R
    Breast Cancer Res Treat; 1996; 40(3):265-70. PubMed ID: 8883969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
    Barbie TU; Ma C; Margenthaler JA
    Ann Surg Oncol; 2015 Nov; 22(12):3861-5. PubMed ID: 25783678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of tamoxifen for breast cancer: twenty-eight years later.
    Jaiyesimi IA; Buzdar AU; Decker DA; Hortobagyi GN
    J Clin Oncol; 1995 Feb; 13(2):513-29. PubMed ID: 7844613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.
    Overgaard M; Jensen MB; Overgaard J; Hansen PS; Rose C; Andersson M; Kamby C; Kjaer M; Gadeberg CC; Rasmussen BB; Blichert-Toft M; Mouridsen HT
    Lancet; 1999 May; 353(9165):1641-8. PubMed ID: 10335782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
    Göbel A; Kuhlmann JD; Link T; Wimberger P; Browne AJ; Rauner M; Hofbauer LC; Rachner TD
    Breast Cancer Res Treat; 2017 Aug; 164(3):737-743. PubMed ID: 28526959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment.
    Love RR; Wiebe DA; Feyzi JM; Newcomb PA; Chappell RJ
    J Natl Cancer Inst; 1994 Oct; 86(20):1534-9. PubMed ID: 7932809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.